Please login to the form below

Not currently logged in
Email:
Password:

When the smoke clears

How has NICE approval and extensive brand building affected Champix' market position?

Competitor brands
On the surface, the established brands' position looks fairly good. The proportions of GPs rating them for each of the five attributes measured have remained fairly stable over the year to date. They may well be seeing increased sales due to more people wanting to stop smoking, but could also be seeing lower market share with the entrance of Champix.

The one note of caution from the survey results comes in the lower proportion of GPs saying they have seen reps or attended seminars/meetings for the established brand - this has fallen by a third. It suggests that these brands may be having difficulties getting their message across in the face of tougher competition.

More GPs say they have seen a rep or attended a meeting hosted by Champix than all of the three established brands combined. In light of recent changes to the working practices of pharmaceutical reps, GPs have a clear reason to see a Champix rep while those from the established brands will face difficulty obtaining appointments without the promise of new information. In the face of such resistance, this suggests the established brands may need to increase their marketing communication activity in order to get their messages across.

BrandWatch is written by Nigel Jacklin, managing director of Objective Research. The data is sourced from Pharmaceutical Brand Monitor, a quarterly survey developed by GP newspaper and MIMS. For further information on the survey contact David Saunders, Haymarket Medical Media on 0208 267 4869 or email at david.saunders@haymarket.com

10th December 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics